Development of a novel glycated protein‐based fibrosis prediction score for determination of significant liver fibrosis in HCV‐infected patients, a preliminary study

Abstract

The current study aimed to investigate the diagnostic value of glycated albumin (GA), glycated hemoglobin (HbA1c), and a number of routine biomarkers as noninvasive indicators of liver fibrosis in patients with chronic hepatitis C (CHC). One hundred patients with CHC were subjected to full medical history and examination, in addition to ultrasound‐guided liver biopsy and histopathological examination for assessment of liver fibrosis stage. GA and HbA1c values, GA/HbA1c ratio, liver function tests, complete blood count, and alpha fetoprotein (AFP) were determined. A novel noninvasive index, dubbed Fibrosis Prediction Score (FPS), was selected for predicting significant liver fibrosis based on total bilirubin, glycated albumin, platelet count, age, and AFP. A validation study for FPS was applied on archival data which include 66 diabetics' patients. The FPS had area under the curve (AUC) of 0.92 for classification of patients with significant fibrosis with 81% sensitivity and 95% specificity. The AUCs of FPS in predicting advanced fibrosis and cirrhosis were 0.86 and 0.82, respectively. Comparison of AST‐to‐platelet ratio index (APRI) and FIB‐4 with FPS indicated increased sensitivity and specificity of FPS over APRI and FIB4 in both significant and advanced fibrosis. FPS has a good sensitivity and specificity for prediction of significant and advanced liver fibrosis in patients with CHC.

A noninvasive diagnostic model for significant liver fibrosis in patients with chronic hepatitis B based on CHI3L1 and routine clinical indicators

“…Liver fibrosis is a serious consequence of CHB, and interrupting the development of liver fibrosis is an important goal of antiviral therapy for CHB patients. Timely diagnosis and dynamic assessment of liver fibrosis can effectively prevent the progression of CHB into cirrhosis or hepatocellular carcinoma (HCC) (2,3). Although liver biopsy remains the gold standard for assessing the degree of liver fibrosis, its clinical application is still limited due to its invasiveness, inconvenience, risk of complications, and sampling errors.…”